Vedanta Biosciences

About:

Vedanta Biosciences creates microbiome-derived therapies to address immune and infectious diseases by modulating the gut microbiota.

Website: http://www.vedantabio.com

Twitter/X: vedantabio

Top Investors: Pfizer, Seventure Partners, Invesco, Bristol-Myers Squibb, KOREA INVESTMENT & SECURITIES

Description:

Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. It includes a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally defined bacterial consortia in powder form to help physicians have access to live bacteria drugs to treat autoimmune and inflammatory diseases easily.

Total Funding Amount:

$437M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2010-01-01

Contact Email:

info(AT)vedantabio.com

Founders:

Alexander Rudensky, Bernat Olle, Dan Littman, David Steinberg, Ruslan Medzhitov

Number of Employees:

101-250

Last Funding Date:

2024-04-30

IPO Status:

Private

© 2025 bioDAO.ai